• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

SurModics Inc.

Surmodics shares drop on Q3 earnings, Sundance DCB wins breakthrough FDA nod

November 1, 2019 By Sean Whooley

SurModics

Surmodics (NSDQ:SRDX) shares plummeted today despite third-quarter results that topped Wall Street projections. Eden Prairie, Minn.-based Surmodics posted profits of $3.55 million, or 26¢ per share, on sales of $30.8 million for the three months ended Sept. 30, moving from red to black on revenue growth of 33.8% compared with Q3 2018. Adjusted to exclude one-time […]

Filed Under: Business/Financial News, Drug-Device Combinations, Featured, Food & Drug Administration (FDA), MassDevice Earnings Roundup, Regulatory/Compliance, Wall Street Beat Tagged With: Surmodics, SurModics Inc.

Surmodics reaps $10m from Abbott on SurVeil balloon milestone

August 28, 2019 By Sean Whooley

SurModics

Surmodics (NSDQ:SRDX) said today that it’s due for a $10 million milestone payment from Abbott (NYSE:ABT) after closing enrollment for the Transcend pivotal trial of its SurVeil drug-coated balloon for treating peripheral artery disease. Abbott in February 2018 paid $25 million up front for the global commercialization rights to the SurVeil device, which uses a proprietary […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Funding Roundup, Wall Street Beat Tagged With: abbott, Medtronic, Peripheral Artery Disease, SurModics Inc.

Surmodics tops Q4 sales estimates, misses on EPS

November 9, 2018 By Sarah Faulkner

SurModics

Shares in Surmodics (NSDQ:SRDX) fell today after the medical device maker topped sales expectations but missed EPS estimates on Wall Street with its fourth-quarter financial results. The Eden Prairie, Minn.-based company was in the red this quarter, posting a net loss of -$1.8 million, or -13¢ per share, on sales of $23 million for the three months […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: SurModics Inc.

VIVA 2018 Roundup: Surmodics reports positive one-year data for SurVeil drug-coated balloon

November 8, 2018 By drugdelivery

VIVA 2018

By Sarah Faulkner & Fink Densford Surmodics (NSDQ:SRDX) touted data this week from an early feasibility study of the company’s SurVeil drug-coated balloon in patients with symptomatic peripheral artery disease due to de novo lesions of the femoral and popliteal arteries. All of the study’s 13 subjects met the acute success measures of safety at […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: SurModics Inc.

Abbott, Surmodics ink $25m deal for drug-coated balloon tech

February 27, 2018 By Sarah Faulkner

Surmodics, Abbott

Abbott (NYSE:ABT) is slated to pay $25 million upfront for the global commercialization rights to Surmodics‘ (NSDQ:SRDX) SurVeil drug-coated balloon, the companies announced today. The company’s drug-device combo, which is in pivotal trials in the U.S., is designed to treat peripheral artery disease in the superficial femoral artery. According to the deal, Abbott could also negotiate […]

Filed Under: Drug-Device Combinations, Featured, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: abbott, SurModics Inc.

Surmodics misses sales estimates in Q1

February 8, 2018 By Sarah Faulkner

SurModics

Shares in Surmodics (NSDQ:SRDX) fell slightly today after the medical device maker missed expectations on Wall Street with its first quarter results. The Eden Prairie, Minn.-based company swung to a net loss of -$1.5 million on sales of $17.0 million for the 3 months ended Dec. 31, for a sales loss of -4% compared with the […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: SurModics Inc.

Surmodics Q4 results top sales, earnings estimates

November 8, 2017 By Sarah Faulkner

SurModics

Shares in Surmodics (NSDQ:SRDX) fell today even though the medical device maker beat expectations on Wall Street with its fourth quarter results. The Eden Prairie, Minn.-based company posted profits of $400,000 on sales of $20.1 million for the 3 months ended Sept. 30, for bottom-line loss of -84.9% on sales growth of 10.4% compared with the […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Wall Street Beat Tagged With: SurModics Inc.

Surmodics goes head-to-head with Medtronic’s drug-coated balloon in pivotal trial

October 23, 2017 By Sarah Faulkner

Surmodics

Surmodics (NSDQ:SRDX) announced today that the first patient was enrolled in a pivotal clinical trial evaluating its SurVeil drug-coated balloon. The 446-patient trial is designed to compare the company’s SurVeil device to Medtronic‘s (NYSE:MDT) In.Pact Admiral drug-coated balloon as a treatment for peripheral artery disease in the upper leg. “Based on the preclinical and early feasibility study […]

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular, Wall Street Beat Tagged With: Medtronic, SurModics Inc.

VIVA 17 Round-up: Medtronic touts real-world data for In.Pact Admiral drug-coated balloon

September 12, 2017 By Sarah Faulkner

Medtronic

Medtronic (NYSE:MDT) touted data for its In.Pact Admiral drug-coated balloon this week at the Vascular Interventional Advances (VIVA) 2017 conference. The company presented two-year, real-world data from the In.Pact Global study, as well as four-year results from the pivotal In.Pact SFA study. Data from the In.Pact Global study showed a 83.3% rate of freedom from clinically-driven target […]

Pages: Page 1 Page 2 Page 3 Page 4 Page 5 Page 6 Page 7

Filed Under: Clinical Trials, Drug-Device Combinations, Featured, Pharmaceuticals, Vascular Tagged With: acotecscientific, C.R. Bard, cook medical, Medtronic, Mercator MedSystems, Royal Philips, SurModics Inc.

SurModics misses on Q2 earnings, narrows outlook

April 27, 2017 By Sarah Faulkner

Surmodics

Shares in SurModics (NSDQ:SRDX) fell today after the medical device maker missed earnings expectations on Wall Street with its 2nd quarter results and narrowed its full-year outlook. The Eden Prairie, Minn.-based company posted profits of $506,000, or 4¢ per share, on sales of $17.5 million for the 3 months ended March 31, for bottom-line loss of […]

Filed Under: Drug-Device Combinations, Featured, MassDevice Earnings Roundup, Wall Street Beat Tagged With: SurModics Inc.

  • Page 1
  • Page 2
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS